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DHEC Onsite Hospital Ebola 
Response Assessments (ERA)
Matthew Crist, MD, MPH 
Medical Consultant 
Division of Acute Disease Epidemiology
DHEC is performing onsite Ebola Response 
Assessments (ERA) of the four hospitals that 
have volunteered to serve as Ebola assessment/
treatment centers in S.C. The ERA Team consists 
of representatives from DHEC’s Division of Acute 
Disease Epidemiology, Public Health Preparedness, 
Bureau of Laboratories, Emergency Medical 
Services, and Environmental Health, to provide the 
necessary expertise to assess the facilities in all 
the domains of preparedness included in the CDC 
Ebola Assessment Tool for the hospitals interested 
in undergoing an ERA Team visit. The Medical 
University of South Carolina was the first to undergo 
an assessment on August 4, 2015. Representatives 
from CDC and the Office of the Assistant Secretary 
for Preparedness and Response participated in this 
initial visit, along with DHEC staff, to provide guidance 
in conducting assessments. Future assessments will 
be performed by DHEC staff as the facilities express 
that they have readied themselves to proceed.
An Overview of Arboviral Disease 
in South Carolina
Chris Evans, MS, PhD 
Public Health Entomologist
Linda J. Bell, M.D. 
State Epidemiologist
Arthropod-borne viruses, or arboviruses, are transmitted 
to humans and animals by arthropods (primarily, but 
not limited to, mosquitoes and ticks). Surveillance data 
show that the range of arboviral diseases is expanding 
as are their vector-competent species of mosquitoes. 
After the introduction of Aedes albopictus (Asian Tiger 
mosquito) into the United States in the mid-1980s, 
the mosquito, which is able to transmit Yellow Fever, 
Dengue, and Chikungunya viruses, has expanded its 
range throughout the southeastern United States into 
the northeast and western parts of the nation. 
Mosquito control activities 
can decrease arboviral 
illnesses by reducing the 
vectors. The activities are 
most often performed 
by local county or city 
governments.  Continued p.2
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Control methods depend on the time of year, the 
mosquito species to be controlled, and the habitat. 
Control methods can include elimination of standing 
water, application of biological insecticides to kill 
mosquito larvae, or spraying insecticides from trucks or 
aircraft to kill adult mosquitoes. Individuals with arboviral 
infections are advised to restrict outdoor activities 
during the time they could be viremic to prevent 
mosquito vectors from acquiring arboviruses when 
taking a blood meal. Arboviral diseases are uncommon, 
but their presence in animals and mosquito vectors 
demonstrates that the risk of infection is present. The 
potential severity of infection highlights the importance 
of mosquito control programs and individual measures 
to protect against exposure to mosquitoes. 
Human cases of arboviral diseases are uncommon in 
South Carolina, but their occurrence varies widely from 
year to year and does not necessarily correlate with the 
occurrence in birds, other animal hosts, or mosquito 
pools. Arboviral diseases may all present initially as an 
acute febrile illness with or without evidence of central 
nervous system infection, thus making all arboviral 
infections possible considerations in the differential 
diagnosis. Arboviral infections may be asymptomatic 
or cause severe illness with progression to acute 
hemorrhagic manifestations or long-term neurologic 
or arthritic sequelae. There are differences in the 
primary vector, the hosts, their distribution, and the 
clinical course. Surveillance data help determine the 
frequency and geographic distribution of human and 
animal arboviral diseases and their vectors. Suspect 
and confirmed cases of arboviral disease are reportable 
to the local county health department within 24 hours 
by phone. Reporting assists public health authorities in 
identifying clusters and implementing control measures 
to reduce future infections. This article provides an 
overview of selected arboviral diseases that occur in 
South Carolina. 
West Nile Virus
West Nile virus (WNV) is the most common mosquito-
borne arbovirus in the U.S. One of the most intense 
outbreaks of WNV in the United States occurred in 2012, 
with 2,873 cases and 286 deaths. Seasonal epidemics 
occur in North America from summer until the second 
or third frost causes mosquito die-offs. Birds are the 
primary host for WNV, and bird die-offs might indicate 
that West Nile virus is circulating between birds and 
mosquitoes in an area. Individuals who report dead 
birds to public health officials can play an important 
role in monitoring West Nile virus. The northern and 
southern house mosquitoes (Culex pipiens complex) 
are the primary mosquito vectors. Humans are most 
commonly infected by mosquitoes; infections from 
blood transfusions or organ transplantation rarely occur. 
WNV activity varies widely in South Carolina from one 
season to the next. Three cases of WNV were reported in 
the state in 2014 with one death. Two cases of individuals 
with viremia, but no symptoms, were also detected 
through the screening of blood donors in 2014. To date in 
2015, WNV has been detected in one bird, two mosquito 
pools, and two asymptomatic blood donors.
The incubation period is typically 2 to 6 days, but ranges 
from 2 to 14 days or longer in immunocompromised 
people. An estimated 70-80 percent of human WNV 
infections are subclinical or asymptomatic. Most 
symptomatic persons experience an acute systemic 
febrile illness that often includes headache, weakness, 
myalgia, or arthralgia; gastrointestinal symptoms and 
a transient maculopapular rash also are commonly 
reported. Most patients with non-neuroinvasive WNV 
disease or WNV meningitis recover completely, but 
fatigue, malaise, and weakness can linger for weeks 
or months. Patients who recover often have residual 
neurologic deficits. Less than 1 percent of infected 
persons develop neuroinvasive disease, which typically 
manifests as meningitis, encephalitis, or acute flaccid 
paralysis. Among patients with neuroinvasive disease, 
the overall case-fatality ratio is approximately 10 
percent, but it is significantly higher for patients with 
WNV encephalitis. 
Dengue and Chikungunya Virus 
Dengue has become established in the continental 
United States. Chikungunya was first documented in the 
Western Hemisphere when cases were identified in the 
Caribbean in 2013. Local transmission of Chikungunya 
has since been identified in 45 countries and territories 
throughout the Americas. The temperate climate and 
use of air conditioning, which keeps mosquitoes out of 
many homes in most of the continental United States, 
makes sustained transmission of these viruses unlikely 
beyond South Florida and the US-Mexico border. South 
Carolina surveillance data show 19 travel-associated 
cases of Chikungunya in 2014, and five or fewer travel-
associated cases of Chikungunya and Dengue have 
been reported in South Carolina to date in 2015. There 
has been no local transmission of either virus detected 
in South Carolina. 
The primary mosquito vectors for Chikungunya and 
Dengue are Aedes aegypti and Aedes albopictus. 
People are the primary hosts of Chikungunya and 
Dengue viruses during epidemic periods. The majority 
(72 to 97 percent) of people infected with Chikungunya 
virus become symptomatic, whereas approximately half 
of Dengue-infected people are asymptomatic. Virus from 
infected individuals can be transmitted to mosquitoes 
up to 18 hours prior to onset of illness and for as long 
as fever is present, potentially contributing to the spread 
Bureau of Disease Control 3
EPI NOTES
of disease. Characteristic symptoms of Chikungunya 
include a sudden onset of fever and severe, debilitating 
pain in many joints for three to 10 days. Joint pains 
can be persistent for months to years. Characteristic 
symptoms of Dengue include nausea/vomiting, 
frontal headache, eye pain, muscle aches, joint pain, 
hemorrhagic manifestations, plasma leakage leading 
to respiratory distress, severe organ involvement, 
and central nervous system impairment. Dengue is 
more likely to cause neutropenia, thrombocytopenia, 
hemorrhage, shock, and death. Both diseases should be 
considered in the differential diagnosis of any individual 
who presents with an acute febrile illness who has 
returned from the Caribbean or any place where the 
diseases are endemic. Distinguishing the diagnosis is 
critical for case management. Suspect Chikungunya 
cases should be managed as Dengue, with avoidance of 
aspirin and non-steroidal anti-inflammatory drugs, until 
it can be ruled out due to the associated hemorrhagic 
manifestations and higher case fatality rate. Co-infection 
with these viruses is possible and has been reported in 
previous outbreaks.
Eastern Equine Encephalitis Virus
Eastern equine encephalitis (EEE) is a rare illness in 
humans, and only a few cases are reported in the United 
States each year, with most occurring in the Atlantic and 
Gulf Coast states. Most people infected with EEE have 
no apparent illness. EEE virus is one of the most severe 
mosquito-transmitted diseases in the United States, 
and approximately 50-90 percent of those who develop 
illness proceed to encephalitis with significant mental 
and physical damage in most survivors. Approximately 
33 percent die. Birds are the reservoir hosts, and the 
black-tailed mosquito, Culiseta melanura, is the vector 
in freshwater swamps. Other mosquito species may be 
bridge vectors that carry the virus out of swamp areas 
into adjoining areas, and transmit the virus to humans, 
horses, and other animals. EEE is identified in horses 
most years in South Carolina, but only one human case 
of EEE has been reported in South Carolina since 2013. 
Other Arboviruses Occurring in  
South Carolina
Outbreaks of other mosquito-borne illnesses  
periodically occur in the United States including La 
Crosse, St. Louis, and California Group encephalitis. 
Most cases of La Crosse disease occur in the upper 
Midwestern and mid-Atlantic and southeastern states. In 
North and South Carolina, it is most commonly detected 
in western mountainous areas. The disease is most 
common in children (especially boys) under the age of 
16 years, and especially those under the age of  
10 years. Many people infected with La Crosse virus 
have no apparent symptoms. 
Prevention of Perinatal Hepatitis 
B Infection
Elona Rhame, RN, MSN, MPH  
Perinatal Hepatitis B Prevention Coordinator 
DHEC Division of Immunization 
803-898-0712 or email rhamele@dhec.sc.gov
Hepatitis B virus (HBV) infection in pregnant women 
poses a serious risk to infants at birth. Approximately 40 
percent of infants born to HBV-infected mothers go on to 
develop chronic infection if recommended post-exposure 
immunoprophylaxis is not administered beginning within 
12 hours of birth. Perinatal Hepatitis B transmission can be 
prevented.
The CDC recommends that all pregnant women be tested 
routinely for hepatitis B surface antigen (HBsAg) during 
each pregnancy, during the first trimester, if possible. 
Testing should be done regardless of past testing results. 
Hepatitis B surface antigen positive results during 
pregnancy must be reported to DHEC within three days. 
Reporting allows prompt initiation of case management 
(see article below).
Visit www.cdc.gov/hepatitis/hbv/perinatalxmtn.htm for 
additional information.
DHEC Perinatal Hepatitis B Case Management
The DHEC Perinatal Hepatitis B Prevention Program 
provides case management for infants born to  
HBsAg-positive mothers. DHEC case managers  
collaborate with prenatal care providers, delivery hospital 
staff, pediatric care providers, and families to assure that 
infants complete recommended post-exposure prophylaxis 
and post-vaccination serologic testing. 
Recomended Management of Infants Born to  
HBsAg-positive Women: 
• Administer single antigen Hepatitis B vaccine and 
Hepatitis B Immune Globulin (HBIG) (0.5 mL) within  
12 hours of birth.
• Complete the vaccine series according to 
recommended schedule for infants born to  
HBsAg-positive mothers within 6 months of birth.
• Assure a referral to DHEC Perinatal Hepatitis B Case 
Management program.
• Conduct post-vaccination serologic testing for anti-HBs 
and HBsAg after completion of the vaccine series, at 
age 9-18 months.
Please contact Elona Rhame at rhamele@dhec.sc.gov 
for additional information on Perinatal Hepatitis B Virus 
transmission and case management.
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Influenza Update for the  
2015–2016 Season
Rebecca Morrison, APRN, MSN, FNP-BC 
Nurse Consultant 
Division of Immunization
Peak influenza activity in the United States can occur 
anytime from November through May but the onset of 
sporadic activity is unpredictable. Getting the current 
flu vaccine as early as possible is recommended 
to provide protection throughout flu season. For 
specific recommendations for the 2015-2016 influenza 
vaccine, see the August 7, 2015, MMWR publication 
“Prevention and Control of Influenza with Vaccines: 
Recommendations of the Advisory Committee on 
Immunization Practices, United States, 2015-16 
Influenza Season.” Major points and updates are 
provided here.
CDC recommends all persons who are 6 months of 
age and older who do not have a contraindication to 
receiving the influenza vaccine. New this season is 
an updated algorithm for determining the appropriate 
number of doses for children 6 months through 8 years 
of age (www.cdc.gov/mmwr/pdf/wk/mm6430.pdf). 
Children in this age group who have previously received 
>2 total doses of trivalent or quadrivalent influenza 
vaccine before July 1, 2015, require only one dose for 
2015-16. Additionally, there is no longer a preference for 
IIV (inactivated influenza vaccine) or LAIV (live attenuated 
influenza vaccine) for healthy children aged 2 through  
8 years when either product is available.
Both trivalent and quadrivalent influenza vaccine 
formulations will be available again this year. Depending 
on the product, influenza vaccine can be administered 
by a variety of routes including intramuscular, 
intradermal, jet injector and nasal spray. The H3N2 
virus strain that was most common last season was 
very different from the H3N2 strain that the vaccine was 
developed to protect against. This resulted in lower than 
usual vaccine effectiveness. Two of the vaccine strains 
included last season were updated for this season, the 
influenza A H3N2 train and the influenza B. Surveillance 
data to date suggests that most circulating viruses are 
well matched to the influenza strains included in this 
year’s seasonal flu vaccine. The 2015-2016 influenza 
vaccine protects against:
• A/California/7/2009 (H1N1)-like virus, 
• A/Switzerland/9715293/2013 (H3N2)-like virus, and 
• B/Phuket/3073/2013-like (Yamagata lineage) virus. 
• The quadrivalent vaccine will protect against these 
strains as well as B/Brisbane/60/2008-like (Victoria 
lineage) virus.
We encourage practitioners to inform your patients of 
the different vaccination options that can help to keep 
them healthy during the influenza season!
Please visit www.scdhec.gov/flu for additional 
information about flu guidance for clinicians and flu 
surveillance and activity in South Carolina.
9-Valent HPV Vaccine: 
Updated HPV Vaccination ACIP 
recommendations
Teresa Foo MD, MPH 
Medical Consultant 
Division of Immunization and Acute Disease Epidemiology
HPV is associated with cervical, vulvar and vaginal 
cancers in females, penile cancer in males and anal 
cancer and oropharyngeal cancer in both females and 
males. HPV infection also leads to cervical precancers 
and genital warts.
On December 10, 2014, the 9-valent HPV vaccine 
(9vHPV) was approved by the Food and Drug 
Administration for use in females aged 9 through 26 
years and males aged 9 through 15 years. The vaccine 
targets HPV types 6, 11, 16 and 18 (similar to the 
quadrivalent HPV vaccine), as well as five additional 
types, HPV types 31, 33, 45, 52 and 58. In the United 
States the majority of all HPV-associated cancers are 
caused by HPV 16 or 18. According to CDC, the 5 
additional types account for about 10–15 percent of 
cervical cancers. Similar to the other approved HPV 
vaccines, the 9vHPV is a 3-dose vaccine. 
Currently, ACIP recommends 9-valent HPV vaccine 
as one of the three HPV vaccines that can be used for 
routine vaccination beginning at age 11 or 12 years 
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for both males and females. ACIP also recommends 
vaccination for females aged 13 through 26 years and 
males aged 13 through 21 years who have not been 
vaccinated previously. Vaccination is also recommended 
through age 26 years for men who have sex with men 
and for immunocompromised persons, including those 
with HIV infection, if not vaccinated previously. 
For a clinician-specific resource sheet which provides 
additional guidance for use of 9-valent HPV vaccination, go 
to www.cdc.gov/hpv/downloads/9vHPV-guidance.pdf 
Ref: Centers for Disease Control and Prevention. Use of 9-valent 
Human Papillomavirus (HPV) Vaccine: Updated HPV vaccine 
Recommendations of the Advisory Committee on Immunization 
Practices. MMWR 2015; 64(11):300-304.
2014 National  
Immunization Survey-Teen  
(NIS-Teen) Data Released
Teresa Foo MD, MPH 
Medical Consultant 
Division of Immunization and Acute Disease Epidemiology
2014 NIS-Teen vaccination coverage estimates were 
released on July 30, 2015. CDC conducts this survey 
via telephone interviews and provider questionnaires 
to assess vaccination coverage among US teens 
aged 13-17 years. Visit www.cdc.gov/mmwr/preview/
mmwrhtml/mm6429a3.htm to read the full MMWR 
article about the 2014 NIS-Teen analysis.
South Carolina HPV data from the 2014 NIS-Teen Survey:
• There was a significant increase from 2013 to 2014  
in ≥2 dose coverage for males from 12.1 percent to 
22.5 percent. 
• There were no significant changes for > 2 dose 
coverage for female with coverage estimates 
from 2013 to 2014 of 53.3 percent to 46.5 percent 
respectively. 
• An estimated 35.9 percent of female SC teens and 
16.1 percent of male SC teens have had ≥3 doses of 
HPV vaccine. 
Coverage findings in the 2014 survey for other vaccines 
showed that South Carolina lagged behind as compared 
to the U.S. for Tdap, 72.6 percent to 87.6 percent, 
and for MenACWY, 67.3 percent to 79.3 percent, 
respectively. HPV coverage for South Carolina teens 
was higher as compared to the U.S. CDC encourages 
health care providers to strongly recommend adolescent 
vaccines to parents of 11 through 18-year-old patients 
and use every opportunity to vaccinate adolescent 
patients. Go to www.cdc.gov/vaccines/who/teens/for-
hcp.html for more information on adolescent vaccines.
Coming Soon: SCIONx
Claire Youngblood 
Statistical /Research Analyst 
Division of Acute Disease Epidemiology
This fall, South Carolina’s Electronic Disease 
Surveillance System (CHESS) will be replaced by a new 
system for reporting infectious disease called SCIONx. 
All current CHESS users will receive email instructions 
and training materials about how to switch to the new 
system in advance of the system going live. Providers 
who are not currently reporting via CHESS will be 
encouraged to start using SCIONx.
Send us an email at SCIONHELP@dhec.sc.gov if you 
would like to be on the mailing list to receive information 
about this new system. 
The Yellow Book
Leon Bullard, MD 
Division of Acute Disease Epidemiology 
Medical Consultant
Early on in their training, all health care 
providers learn how to take a history 
and perform a physical examination. 
The lists of questions that are to be 
asked and methods of documentation 
of the answers are extensive; even with the utilization of 
electronic health records. An often overlooked component 
of the interview, unfortunately, is the travel history. Because 
of newly emerging infectious diseases (many of which are 
uncommon in our locale) or the re-emergence of old known 
diseases, being just a short flight away one must be aware 
of the recent travels of the person seeking care.
Primary care providers or health care staff in Urgent Care 
facilities or Emergency Departments may encounter 
persons with febrile illnesses, rash illnesses or symptom 
complexes atypical to “what is going around.” A detailed 
travel history might point the provider to the correct 
diagnostic pathway.
Readers of the EpiNotes should be aware of the advice 
available from the Centers for Disease Control and 
Prevention: wwwnc.cdc.gov/travel. 
Attention is directed to the online availability of The Yellow 
Book, 2016 Edition; this is also known as CDC Health 
Information for International Travel. 
Also available for information concerning diseases 
associated with international travel is the World Health 
Organization (WHO) site: www.who.int/ith/en.
Specific questions pertaining to travel associated illnesses 
may be directed to DHEC’s Division of Acute Disease 
Epidemiology at 803-898-0961.
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South Carolina Muscular 
Dystrophy STARnet
Michael Smith, MSPH 
Bureau of Maternal and Child Health
Muscular dystrophies (MD) are a group of genetic 
diseases characterized by progressive muscle weakness 
and muscle cell death. There are nine major types of 
MD which vary by severity of muscle weakness, age of 
onset, rate of progression, affected genes and mode of 
inheritance. Types of MD include myotonic, congenital, 
Emery-Dreifuss, facioscapulohumeral, oculopharyngeal, 
limb-girdle, Duchenne and Becker. Duchenne and 
Becker MD are the most common, with Duchenne being 
the most severe condition. 
In 2001, the federal government passed the Muscular 
Dystrophy Care Act to allow provisions for MD research. 
The Centers for Disease Control and Prevention created 
and funded the Muscular Dystrophy Surveillance, 
Tracking, and Research Network (MD STARnet) in 
response to the legislation. The primary goal of MD 
STARnet is to collect high-quality epidemiological data 
on the diagnosis, services, treatments, support, and 
care related to muscular dystrophies. 
There are currently six sites participating: Colorado, 
Iowa, Utah, North Carolina, Western New York and 
South Carolina. South Carolina received funding to 
begin participation during the initiation of Phase III of 
the MD STARnet project. Here in the Palmetto State, we 
have a collaborative effort between DHEC, the Health 
and Demographics Section of the Office of Revenue and 
Fiscal Affairs (RFA) and the University of South Carolina 
School of Public Health. Our goals include: 
1. to maintain a dynamic surveillance system for 
muscular dystrophy that capitalizes on the strengths 
of the medical record and administrative data 
available in South Carolina, and 
2. to develop and manage a data system that allows 
us to conduct ongoing analyses of health care 
utilization, costs, and community participation of 
people with these conditions. 
Beginning in late August, DHEC Nurses will start active 
data collection and continue the process throughout 
Phase III which will last until 2019. During this time, the 
South Carolina MD STARnet team will collect data from 
other sources, including vital records, and administrative 
and claims data from state-wide health clinics. South 
Carolina data will be pooled with data from the other 
sites to create a single, robust data set that will provide 
valuable information about MD in the US. 
Contact John Clarkson, MPH at clarksjg@dhec.sc.gov 
for additional questions regarding STARnet.
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Disease Reporting
For immediate and urgently reportable conditions, call 
your regional health department:
• Lowcountry: 843-441-1091
• Midlands: 888-801-1046
• Pee Dee: 843-915-8845
• Upstate: 866-298-4442
• DHEC Bureau of Disease Control: 803-898-0861 
After-hours: 1-888-847-0902
Routine reports may be phoned in to your regional 
health department or faxed/mailed on a completed  
2015 South Carolina Department of Health and 
Environmental Control Disease Reporting Form:  
www.scdhec.gov/library/D-1129.pdf 
Contact information, including mailing addresses 
and fax numbers, are found on the List of Reportable 
Conditions: www.scdhec.gov/library/CR-009025.pdf
Contact the Bureau of Disease Control
Virginie Daguise, PhD, Director 
803-898-0713
Linda Bell, MD, State Epidemiologist 
803-898-0861
Dana Giurgiutiu, PhD, MPH, Director 
Division Acute Disease Epidemiology 
803-898-0933
DHEC Bureau of Disease Control 
2100 Bull Street 
Columbia, SC 29201 
www.scdhec.gov 
803-898-0558
Bureau of Disease Control Divisions
Division of Acute Disease Epidemiology 
803-898-0861
Division of Immunization and Prevention 
1-800-277-4687
Division of STD/HIV 
803-898-0749
Division of Surveillance and Technical Support 
803-898-0749
Division of Tuberculosis Control 
803-898-0558
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Epi Notes, DHEC’s epidemiology 
publication, is published in an  
online format.
Continue to receive our updates:
• To subscribe to the Epi Notes for email delivery, send 
an email to EpiNotes@dhec.sc.gov with “Subscribe” 
in the subject line.
• Epi Notes is also available from the DHEC website:  
www.scdhec.gov/Health/DiseasesandConditions/
ChronicDiseaseData/EPINotes
If you are a health professional interested in 
receiving health notifications from the South 
Carolina Health Alert Network, please email 
SCHAN@dhec.sc.gov
FLU WATCH
Flu season has arrived. Be sure to check DHEC’s 
weekly Flu Watch for updates on influenza 
activity in South Carolina.
• Type “Flu Data” in the search box on DHEC’s 
home page, or
• Bookmark DHEC’s 2015-2016 Flu in South 
Carolina page in your browser:  
www.scdhec.gov/Health/
DiseasesandConditions/InfectiousDiseases/
Flu/FluData
